Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that makes a lot of sense I agree
provided the results are good IMO yes
Im not going to lie I think the delay of TLD + publication is beyond absurd as well.
They better come with more than the article alone cause that is now just not good enough anymore.
Yes I know I was there ;) lol
But I now get what you meant
If the plaintiff can demonstrate they had no or could not have prior knowledge about the foul play (for reasons of covering it up) by the third party then that is correct.
However, if even this board had knowledge about stock manipulation then how can NWBO maintain they just did know. I think any claim of liability for stock manipulation is going to be extremely difficult for NWBO after all this time has passed. They just should not have waited this long IF we will ever see any such claim for suffered damages by NWBO which I highly doubt tbh.
well then they better hurry the hell up since the limitation period of an unlawful act such as stock manipulation is generally six years. The limitation period starts running from the date of the breach occurs or the tort is committed.
In fact, I think they may already be too late if they have not filed any liability with any third party yet.
But wait... speed and continuous urgency is one of LP specialties. lol
I am convinced the article is in peer review and the delay is due to obstacles in the peer-reviewing process
the mother of all news will ofcourse be TLD + publication not only because the approval will indicate future revenue but foremost the speculation of an acquiring of NWBO against a much higher SP (and an uplist before that) can then begin.
Thank you. That I knew already and now in peer review (As DI told us) with delay in the peer reviewing unfortunately. Hopefully sorted out soon
Lol that’s what always happens. Im long in anavex a tiny bit and I believe the big gain is still ahead of the stock. Im planning to increase my position after NWBO TLD but probably then the stockp will be x2 what it is now. If anavex will get approved for Alzheimer’s boy oh boy that would mean a MC of 25 billion at least
Are you long in AVXL flipper if I may ask?
mistyped I mean market revenue
if I have to give it a stab then I think the delay is due to peer review going back and forward.
It would equally not surprise me if NWBO has waited for Uk approval
good, grief everyone knows that when I said market size I, of course, meant measured in revenue, not in numbers of patients. I assumed such a simple fact would be known by everyone.
right now I just want the journal and TLD. If the stock price would after that only tick the old ATH then Im more than happy, sell and move on.
that is an odd way of comparing market size, the rarity of the disease.
I did not assert that the number of GBM patients is as high as women with breast cancer which is also odd to look at it.
Treating a patient with GBM is way more expensive and has a higher price than treating a patient with breast cancer resulting in approx the same market revenue. In other words 10,000 x 10 is the same as 100 x 1000
This may help in your quest what L could be valued at as a stand alone
https://finance.yahoo.com/news/worldwide-glioblastoma-multiforme-industry-2030-114500235.html?guccounter=1
That does not present any medical statistical evidence Direct works whatsoever. I think it works I think NWBO holds gold. Its not to convince me.
There is no data indicating that Direct works as we have seen at least at the level of the blinded blended data from L for other organs. And there is no active trial.
yes I know they have treated a few patients (among Thermo's brother if I recall correctly) with Direct which looked very promising.
However, since Direct is NOT an active trial worse there is no other active trial at present with NWBO and the data from the few single Direct patients are insufficient to prove any statistical medical evidence one can not call it a platform yet. This is entirely NWBO's choice.
So theoretically there could be a platform however in practice there is none. (IMO) the reactivating of the platform is up to the acquiring company buying NWBO, they have all patents in place todo so.
because it is apparently such an emotional subject I have decided to once and for all prove my point see tradingview chart:
1. From Jan - 1/2 march 2021 nwbo and XBI performed in the same manner
2. From 1/2 march 2021 - aug 2021 NWBO outperformed XBI.
3. From Aug 2021 - 1/2 Nov 2021 NWBO and XBI performed on average in the same manner
4. From 1/2 nov - end dec. NWBO declined worse than XBI thus NWBO underperformed XBI
5. Jan - Feb 9 NWBO increased from a worse position while XBI decreased
6. and now XBI and NWBO have paired up again.
So over the course of the last 12 months, NWBO and XBI performed the same for investors. If you would have invested $ 1000 in NWBO and in XBI on Jan 1 2021 and compared it with today you would not have been worse or better off by one or the other. Which is my whole point
It is normal to measure the last 12 months, not a timeframe a subjective investor would like to observe to fit its biased narrative.
The only treatment NWBO is after getting approved is for GBM. Thats it.
If they want approval for lung, colon, pancreatic, liver, ovarian, head and neck, and others for all Types of Inoperable Solid tumors they will have to conduct trials.
Facts:
If you think that LP will on her blue eyes just gain approval for anything outside GBM after GBM data without conducting new trials then I cant help you. Ofcourse new trials need to be started to prove there is a platform.
No NWBO SP did NOT outperform the XBI benchmarked it has now paired up after it first underperformed.
NWBO journal article is late due to peer review back and forwards which is taking way longer than usual with other medical journal publications.
Im measuring it from the decline of biotech and you from the beginning of the year which is highly arbitrarily.
NWBO has caught up with XBI which before that had lacked behind with, great. If it now overtakes XBI then we are doing better.
Its called the measurement of the bench market.
https://www.investopedia.com/articles/investing/032516/how-use-benchmark-evaluate-portfolio.asp
yes on paper, in reality, a biotech has to prove that by conducting other trials than the main one. NWBO is not conducting any trials at present and thus until they do they are not developing their MOA outside GBM, their platform. If tomorrow they would announce they have continued any of their discontinued Direct trials then yes then from that moment on they are developing a platform by trying to prove the MOA works outside GBM. Now they have no platform only a GBM treatment.
NWBO has declined more than the XBI over the last 6 months prior to dec 31 and has now since the start of the year caught up, that's no progress that's making up for lost ground towards XBI since the decline of small biotech 6 months ago.
Now XBI and NWBO have the same decline -26% and thus the same performance. Its really not that difficult.
NWBOs GBM trial data will show that they knocked the ball out of the park I have zero doubt about that.
They dont have a platform. They only have a platform in name and on paper. They have a platform when they actually run more trials on the same MOA of the drug outside GBM
They only have a successful Phase 3 trial for the treatment of GBM that's, not a platform.
you are misinformed NWBO is NOT crushing XBI.
Jeez NWBO gains of what it lost before more than the XBI did over the last 6 months, how difficult is that for you? If don't understand simple math dont respond.
it all depends on the small biotech index which NWBO lacks behind. XBI up 5% NWBO 2%. Without news I dont see NWBO beating XBI. If small biotech craters NWBO goes down as well H and S or not.